SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

FDC spurts on introducing stronger versions of Favipiravir Drugs PiFLU, Favenza

30 Oct 2020 Evaluate

FDC is currently trading at Rs. 344.05, up by 3.65 points or 1.07% from its previous closing of Rs. 340.40 on the BSE.

The scrip opened at Rs. 349.00 and has touched a high and low of Rs. 350.25 and Rs. 339.15 respectively. So far 6912 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 378.00 on 29-Sep-2020 and a 52 week low of Rs. 165.65 on 24-Mar-2020.

Last one week high and low of the scrip stood at Rs. 353.00 and Rs. 337.50 respectively. The current market cap of the company is Rs. 5875.49 crore.

The promoters holding in the company stood at 69.24%, while Institutions and Non-Institutions held 10.39% and 20.37% respectively.

FDC has launched new strength variants of its Favipiravir brands - PiFLU and Favenza, used to treat mild to moderate cases of COVID-19 in India. These prescription-only drugs will be available at all retail medical outlets and hospital pharmacies across the country, from November 1, 2020.

The 800mg version of the drugs will help reduce the number of tablets to be taken by any patient by 75%. Currently patients are required to take 18 pills on the first day followed by 8 tablets every day for the next 13 days.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).

FDC Share Price

427.35 7.05 (1.68%)
30-Jun-2026 14:27 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1873.60
Dr. Reddys Labs. 1368.45
Cipla 1471.20
Zydus Lifesciences 1121.15
Lupin 2436.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: